Ozempic Access: Essential Medicines List Expansion

Summary of ⁣the⁤ Text: GLP-1 Drugs & WHO’s Essential Medicines List

This text discusses the recent inclusion of GLP-1 receptor agonist drugs (like Ozempic, Wegovy, Zepbound, and Mounjaro) on the World Health⁣ organization’s (WHO) list of essential medicines. Here’s a breakdown of the key points:

How these drugs work: These medications mimic the effects of the hormone⁤ GLP-1, which is ⁣released after ⁢meals. GLP-1 stimulates insulin production (helping diabetics) and signals the ⁤brain to create a feeling of fullness (aiding weight loss). Benefits beyond weight loss: The ⁣WHO⁣ highlights that these drugs can⁤ improve ⁣blood sugar control⁤ in ⁢type 2 diabetes, reduce the risk of cardiovascular and kidney complications, promote⁤ weight loss, and possibly reduce premature ⁤death, especially for those with kidney or heart ⁣failure.
Access is a major issue: ‍The high cost of these drugs currently limits access for many who coudl benefit.
WHO’s goal: ‍ Including these drugs on the essential medicines list aims to improve access by⁤ encouraging competition from generic manufacturers and prioritizing patients⁤ who would benefit the‍ most, especially in underserved ⁢areas.
Broader context: ⁢ The text emphasizes the significant financial burden of medicines for noncommunicable diseases and the need for equitable access through strong health systems ⁣and political will.

In essence, the ⁤article explains why these increasingly popular weight loss drugs are being recognized as essential medicines and what* the WHO is⁢ doing to make them more widely available.